Dr. Mohammed is a world recognized authority in the fields of medical genomics and personalized medicine. He is a Forbes-listed executive and has been the recipient of multiple academic and industry awards. He is the holder of several patents in the general fields of molecular diagnostics and genomics research, and is one of the most frequent national and international conference speakers in the genre.
While completing his clinical post-doctoral internship at the University of California, Los Angeles (UCLA), Dr. Mohammed was credited with discovering one of two genomic pathways that define drug resistance to the Novartis blockbuster therapy, Gleevec, and co-published these findings in the journal Science (2001) with the renowned oncologist Dr. Charles Sawyers (current Chair of Human Oncology, Memorial Sloan-Kettering). That same year, he was the co-author of the American Society of Human Genetics’ Paper of the Year Award with his mentor, Dr. Eric Vilain (current Chief of Pediatric Genetics, UCLA), for their discovery of the role of the Wnt4 gene in sex-reversal. These early studies helped to define Dr. Mohammed as one of the few genomics specialists with core competencies in both the genomic characteristics of childhood development, as well as the genomic etiology of oncology/cancer. Considered by Dr. Mohammed as one of the highlights of his career, he shared the podium with the Director of the NIH, Dr. Francis Collins, as one of the invited plenary speakers at the World Human Genome Organization (HUGO) meeting (Cancun, Mexico 2003) to commemorate the 50th anniversary of the discovery of the DNA double helix.
Concomitant with his postdoctoral fellowship at Baylor College of Medicine (2001), Dr. Mohammed was instrumental in the development and commercialization of the industry’s first available comparative genomic hybridization (CGH) arrays. Consequently, he has the distinction of being one of the primary innovators in the diagnostic application of genomic microarrays and is one of the most published authors in that field. He was the co-primary author of the first peer-reviewed study utilizing microarray CGH techniques in the clinical diagnosis of developmental abnormalities (2002) and later (2008) was the senior author of the first peer-reviewed study utilizing microarray CGH techniques for clinical oncology purposes. The CGH technologies that Dr. Mohammed helped to innovate and commercialize have continued to revolutionize the understanding of the human genome and have spawned thousands of peer-reviewed papers across the international academic community.
Dr. Mohammed was a founder (2001) and Director of Research and Development at Spectral Genomics Inc., a world pioneer in the field of microarray CGH technologies. Under Dr. Mohammed’s scientific stewardship Spectral Genomics quickly grew from a start-up funded by Baylor College of Medicine, to an innovative authority in the then emerging field of medical genomics, which was eventually acquired by PerkinElmer Inc.
With the acquisition of Spectral Genomics, Dr. Mohammed was invited to head the (then) brand new Advanced Technologies Department at the world’s largest diagnostics reference laboratory, Quest Diagnostics Inc. (2003-2006). Overseeing a state of the art facility at Quest, he was responsible for designing the roadmap and executing the adoption of new diagnostic technologies for this Fortune 500 Company (Market Capitalization exceeding 8 billion US). Within his first year at Quest, Dr. Mohammed was honored with the Patent Innovation Award for prolific innovations and discoveries and notably during his tenure was the youngest recipient of the Medical Innovation Award; Quest’s highest and most prestigious employee recognition award.
In 2006, Dr. Mohammed was recruited to co-found and lead the development of Combimatrix Molecular Diagnostics (CMDX). He served as the latter’s Chief Scientific Officer, Chief Operating Officer and for his last 4 years of tenure, as Chief Executive Officer. Under his leadership, CMDX became the first diagnostic company offering genomic microarray-based diagnostics to receive an official “freedom to operate” clearance by the FDA. Moreover, under his guidance, CMDX developed and launched the most comprehensive portfolio of clinically validated genomics based tests in the industry and witnessed 9 consecutive quarters of financial growth with its stock price growing from ~$4/share to over $16/share (Nasdaq).
After a decade of intense professional growth, and with an extensive network of academic and industrial colleagues, Dr. Mohammed left CMDX in October 2010 to pursue the launch of his own firm, ManaGeneDx Inc. ManaGeneDx is focused on providing best-in-class consulting services to the personalized medicine and diagnostic service sectors. It capitalizes on Dr. Mohammed’s unique breadth and depth of experience (bench-side to boardroom--diagnostic lab to medical clinic) to help companies and clinics navigate through the complex ecosystem characteristic of personalized diagnostics and medicine initiatives. ManaGeneDx counts as its clients, medical clinics, diagnostic companies and research institutes in the US, Canada, Europe, Asia and the Middle East.
Dr. Mohammed serves on the Canadian Board of Autistic Research and is a consultant to the world-renowned Toronto Center of Applied Genomics. He has had the honor of being the personal guest of the Premiere of Ontario, the Honorable Dalton McGuinty, and on several occasions, the guest of the Canadian Consulate of California. He has also sat on several think tank panels, including ones from the FDA and National Institute of Health (NIH) and is a frequent academic lecturer on the role of genomics in medicine.